AxisBiotix-Ps™ se lanzará en Amazon Reino Unido
SkinBioTherapeutics plc
("SkinBioTherapeutics" o "la Compañía")
AxisBiotix-Ps? to launch on Amazon UK
30 November 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health announces that its AxisBiotix-Ps? food supplement will launch on Amazon.co.uk from Wednesday, 6 December 2023 at 9am.
The launch of a sales channel through Amazon is a key part of the commercialisation strategy to expand market share for AxisBiotix-Ps?. The first Amazon launch is in the UK; the aim is then to extend product availability through other Amazon country sites. Management is already proactively seeking to expand online sales of its AxisBiotix-Ps? into the European countries where the product has regulatory clearance (France, Italy and Spain).
AxisBiotix-Ps? first went on sale to UK in October 2021 and is intended for customers to alleviate sensitive skin conditions such as psoriasis. The response from customers continues to be very positive with the retention rates of AxisBiotix-Ps? in the UK staying at 80% or above. If access to the product Puede ser hecho simpler, via an online channel like Amazon which is familiar to the majority of people, then management believes this will empujón sales and marketing efforts.
According to Mintel, approximately 90% of the UK adult population uses Amazon. In 2019 alone, the UK e-commerce market was the largest in Europe and third largest to China and the US. Amazon held 30% of this market, and has shown ambitions in the beauty and skincare markets, with the launch of its own-brand skin care line, Belei. It has also teamed up with beauty major, L'Oreal.
Stuart J. Ashman, CEO of SkinBioTherapeutics, dijo: "The skin care market is a significant market, with an increasing global focus on health and well-being, and the demand for science-backed supplements is at an all-time high. The primary focus for AxisBiotix-Ps? is growing our share of the market and using a sales channel like Amazon, which we use everyday, makes good strategic sense. We hope to announce the European launches on Amazon before the end of the year."
-Fin-
Para más información, por favor contacte:
Notas a los editores Acerca de SkinBioTherapeutics plc SkinBioTherapeutics es una empresa de ciencias de la vida centrada en la salud de la piel. La tecnología de plataforma patentada de la empresa, SkinBiotix®, se basa en los descubrimientos realizados por la profesora Catherine O'Neill y el profesor Andrew McBain. La empresa se dirige a varios sectores del cuidado de la piel, los más avanzados de los cuales son el cuidado cosmético de la piel y los complementos alimenticios para modular el sistema inmunológico aprovechando el eje intestino-piel. En cada área, SkinBioTherapeutics planea ejemplificar su tecnología a través de estudios en humanos. El primer producto de la compañía, AxisBiotix-Ps?, un complemento alimenticio para abordar los síntomas de la psoriasis leve a moderada. La empresa cotizó en AIM en abril de 2017 y tiene su sede en Newcastle, Reino Unido. Para más información visite: www.skinbiotherapeutics.com y www.axisbiotix.com.
|
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.